Experimental validation of the complement protein C3a down expression in the plasma of patients with squamous cell carcinoma of the penis
Abstract Objectives We have previously shown the importance of the complement system in differentiating between patients with squamous cell carcinoma of the penis (SCCP) and controls. These patients had low expression of C3a and C4 fragments. Therefore, in this study, we investigated the complement...
Gespeichert in:
| Veröffentlicht in: | Urologic oncology 2017-09, Vol.35 (9), p.545.e13-545.e18 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 545.e18 |
|---|---|
| container_issue | 9 |
| container_start_page | 545.e13 |
| container_title | Urologic oncology |
| container_volume | 35 |
| creator | Ornellas, Paulo, M.D Ribeiro-Carvalho, Marilza de M., Ph.D Ornellas, Antonio Augusto, Ph.D., M.D Scherrer, Luciano, M.S Koifman, Leandro, M.D Magni, Fulvio, Ph.D Ornellas, Maria Helena, M.D., Ph.D Alves, Gilda, Ph.D |
| description | Abstract Objectives We have previously shown the importance of the complement system in differentiating between patients with squamous cell carcinoma of the penis (SCCP) and controls. These patients had low expression of C3a and C4 fragments. Therefore, in this study, we investigated the complement protein C3a as a potential circulating biomarker in these patients by a commercially available enzyme-linked immunosorbent assay (ELISA) test. Patients and methods Plasma samples from 39 patients with SCCP, 15 patients with prostate cancer, and 50 healthy male subjects were evaluated using the ELISA—Bioscience OptEIA Kit human anti-C3a (BD). The nonparametric Mann-Whitney test was used for comparison of means among the groups. Results The complement protein C3a was found down expressed in patients with SCCP ( P |
| doi_str_mv | 10.1016/j.urolonc.2017.05.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1903438633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143917302120</els_id><sourcerecordid>1903438633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-d267c2b96846ace94dba140f323fd857d9d537a9da3a05acff6463c00db0da273</originalsourceid><addsrcrecordid>eNqFUsuO1DAQjBCIXRY-AeQjl4T2I68LCI2Wh7QSB-BseeyO1oNjZ-1kH5_AX2MzAwcunGzZVdXdVV1VLyk0FGj35tBsMbjgdcOA9g20DQB7VJ3Toec1E2P3ON-hH2oq-HhWPUvpAEDFQOnT6owNbctE155XPy_vF4x2Rr8qR26Vs0atNngSJrJeI9FhXhyWb7LEsKL1ZMcVMeHOE7xfIqZU0Pm5oBen0qwKd8kqmZTInV2vSbrZ1By2RDQ6R7SK2vpwBP6mobfpefVkUi7hi9N5UX3_cPlt96m--vLx8-79Va0Fg7U2rOs124_dIDqlcRRmr6iAiTM-maHtzWha3qvRKK6gVXqaOtFxDWD2YBTr-UX1-qib57nZMK1ytqn0pTzmFiUdgQs-dJxnaHuE6hhSijjJJVul4oOkIEsK8iBPKciSgoRW5hQy79WpxLaf0fxl_bE9A94dAZgHvbUYZdLZLo3GRtSrNMH-t8TbfxS0s95q5X7gA6ZD2KLPLkoqE5Mgv5ZVKJtAew6MMuC_AEbCs3c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1903438633</pqid></control><display><type>article</type><title>Experimental validation of the complement protein C3a down expression in the plasma of patients with squamous cell carcinoma of the penis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ornellas, Paulo, M.D ; Ribeiro-Carvalho, Marilza de M., Ph.D ; Ornellas, Antonio Augusto, Ph.D., M.D ; Scherrer, Luciano, M.S ; Koifman, Leandro, M.D ; Magni, Fulvio, Ph.D ; Ornellas, Maria Helena, M.D., Ph.D ; Alves, Gilda, Ph.D</creator><creatorcontrib>Ornellas, Paulo, M.D ; Ribeiro-Carvalho, Marilza de M., Ph.D ; Ornellas, Antonio Augusto, Ph.D., M.D ; Scherrer, Luciano, M.S ; Koifman, Leandro, M.D ; Magni, Fulvio, Ph.D ; Ornellas, Maria Helena, M.D., Ph.D ; Alves, Gilda, Ph.D</creatorcontrib><description>Abstract Objectives We have previously shown the importance of the complement system in differentiating between patients with squamous cell carcinoma of the penis (SCCP) and controls. These patients had low expression of C3a and C4 fragments. Therefore, in this study, we investigated the complement protein C3a as a potential circulating biomarker in these patients by a commercially available enzyme-linked immunosorbent assay (ELISA) test. Patients and methods Plasma samples from 39 patients with SCCP, 15 patients with prostate cancer, and 50 healthy male subjects were evaluated using the ELISA—Bioscience OptEIA Kit human anti-C3a (BD). The nonparametric Mann-Whitney test was used for comparison of means among the groups. Results The complement protein C3a was found down expressed in patients with SCCP ( P <0.05) in comparison to either subjects with good health or subjects with prostate cancer. Conclusion Experimental validation of the down expression of C3a was well succeeded using a commercial ELISA kit. Complement system fragment C3a is down expressed in patients with SCCP. Besides, C3a is also low expressed in the plasma of patients with initial prostate cancer when compared to healthy subjects. These results suggest that the innate immune response might be suppressed in patients with these malignancies.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2017.05.002</identifier><identifier>PMID: 28552465</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - metabolism ; Carcinoma, Squamous Cell - genetics ; Carcinoma, Squamous Cell - pathology ; Circulating biomarker ; Complement C3a - metabolism ; Enzyme-linked immunosorbent assay (ELISA) ; Enzyme-Linked Immunosorbent Assay - methods ; Healthy Volunteers ; Human complement C3a-desArg/C4a-desArg ; Humans ; Male ; Middle Aged ; Penile cancer ; Penile Neoplasms - genetics ; Penile Neoplasms - pathology ; Plasma ; Tumor microenvironment ; Urology</subject><ispartof>Urologic oncology, 2017-09, Vol.35 (9), p.545.e13-545.e18</ispartof><rights>Elsevier Inc.</rights><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-d267c2b96846ace94dba140f323fd857d9d537a9da3a05acff6463c00db0da273</citedby><cites>FETCH-LOGICAL-c420t-d267c2b96846ace94dba140f323fd857d9d537a9da3a05acff6463c00db0da273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1078143917302120$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28552465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ornellas, Paulo, M.D</creatorcontrib><creatorcontrib>Ribeiro-Carvalho, Marilza de M., Ph.D</creatorcontrib><creatorcontrib>Ornellas, Antonio Augusto, Ph.D., M.D</creatorcontrib><creatorcontrib>Scherrer, Luciano, M.S</creatorcontrib><creatorcontrib>Koifman, Leandro, M.D</creatorcontrib><creatorcontrib>Magni, Fulvio, Ph.D</creatorcontrib><creatorcontrib>Ornellas, Maria Helena, M.D., Ph.D</creatorcontrib><creatorcontrib>Alves, Gilda, Ph.D</creatorcontrib><title>Experimental validation of the complement protein C3a down expression in the plasma of patients with squamous cell carcinoma of the penis</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>Abstract Objectives We have previously shown the importance of the complement system in differentiating between patients with squamous cell carcinoma of the penis (SCCP) and controls. These patients had low expression of C3a and C4 fragments. Therefore, in this study, we investigated the complement protein C3a as a potential circulating biomarker in these patients by a commercially available enzyme-linked immunosorbent assay (ELISA) test. Patients and methods Plasma samples from 39 patients with SCCP, 15 patients with prostate cancer, and 50 healthy male subjects were evaluated using the ELISA—Bioscience OptEIA Kit human anti-C3a (BD). The nonparametric Mann-Whitney test was used for comparison of means among the groups. Results The complement protein C3a was found down expressed in patients with SCCP ( P <0.05) in comparison to either subjects with good health or subjects with prostate cancer. Conclusion Experimental validation of the down expression of C3a was well succeeded using a commercial ELISA kit. Complement system fragment C3a is down expressed in patients with SCCP. Besides, C3a is also low expressed in the plasma of patients with initial prostate cancer when compared to healthy subjects. These results suggest that the innate immune response might be suppressed in patients with these malignancies.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Carcinoma, Squamous Cell - genetics</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Circulating biomarker</subject><subject>Complement C3a - metabolism</subject><subject>Enzyme-linked immunosorbent assay (ELISA)</subject><subject>Enzyme-Linked Immunosorbent Assay - methods</subject><subject>Healthy Volunteers</subject><subject>Human complement C3a-desArg/C4a-desArg</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Penile cancer</subject><subject>Penile Neoplasms - genetics</subject><subject>Penile Neoplasms - pathology</subject><subject>Plasma</subject><subject>Tumor microenvironment</subject><subject>Urology</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuO1DAQjBCIXRY-AeQjl4T2I68LCI2Wh7QSB-BseeyO1oNjZ-1kH5_AX2MzAwcunGzZVdXdVV1VLyk0FGj35tBsMbjgdcOA9g20DQB7VJ3Toec1E2P3ON-hH2oq-HhWPUvpAEDFQOnT6owNbctE155XPy_vF4x2Rr8qR26Vs0atNngSJrJeI9FhXhyWb7LEsKL1ZMcVMeHOE7xfIqZU0Pm5oBen0qwKd8kqmZTInV2vSbrZ1By2RDQ6R7SK2vpwBP6mobfpefVkUi7hi9N5UX3_cPlt96m--vLx8-79Va0Fg7U2rOs124_dIDqlcRRmr6iAiTM-maHtzWha3qvRKK6gVXqaOtFxDWD2YBTr-UX1-qib57nZMK1ytqn0pTzmFiUdgQs-dJxnaHuE6hhSijjJJVul4oOkIEsK8iBPKciSgoRW5hQy79WpxLaf0fxl_bE9A94dAZgHvbUYZdLZLo3GRtSrNMH-t8TbfxS0s95q5X7gA6ZD2KLPLkoqE5Mgv5ZVKJtAew6MMuC_AEbCs3c</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Ornellas, Paulo, M.D</creator><creator>Ribeiro-Carvalho, Marilza de M., Ph.D</creator><creator>Ornellas, Antonio Augusto, Ph.D., M.D</creator><creator>Scherrer, Luciano, M.S</creator><creator>Koifman, Leandro, M.D</creator><creator>Magni, Fulvio, Ph.D</creator><creator>Ornellas, Maria Helena, M.D., Ph.D</creator><creator>Alves, Gilda, Ph.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>Experimental validation of the complement protein C3a down expression in the plasma of patients with squamous cell carcinoma of the penis</title><author>Ornellas, Paulo, M.D ; Ribeiro-Carvalho, Marilza de M., Ph.D ; Ornellas, Antonio Augusto, Ph.D., M.D ; Scherrer, Luciano, M.S ; Koifman, Leandro, M.D ; Magni, Fulvio, Ph.D ; Ornellas, Maria Helena, M.D., Ph.D ; Alves, Gilda, Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-d267c2b96846ace94dba140f323fd857d9d537a9da3a05acff6463c00db0da273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Carcinoma, Squamous Cell - genetics</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Circulating biomarker</topic><topic>Complement C3a - metabolism</topic><topic>Enzyme-linked immunosorbent assay (ELISA)</topic><topic>Enzyme-Linked Immunosorbent Assay - methods</topic><topic>Healthy Volunteers</topic><topic>Human complement C3a-desArg/C4a-desArg</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Penile cancer</topic><topic>Penile Neoplasms - genetics</topic><topic>Penile Neoplasms - pathology</topic><topic>Plasma</topic><topic>Tumor microenvironment</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ornellas, Paulo, M.D</creatorcontrib><creatorcontrib>Ribeiro-Carvalho, Marilza de M., Ph.D</creatorcontrib><creatorcontrib>Ornellas, Antonio Augusto, Ph.D., M.D</creatorcontrib><creatorcontrib>Scherrer, Luciano, M.S</creatorcontrib><creatorcontrib>Koifman, Leandro, M.D</creatorcontrib><creatorcontrib>Magni, Fulvio, Ph.D</creatorcontrib><creatorcontrib>Ornellas, Maria Helena, M.D., Ph.D</creatorcontrib><creatorcontrib>Alves, Gilda, Ph.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ornellas, Paulo, M.D</au><au>Ribeiro-Carvalho, Marilza de M., Ph.D</au><au>Ornellas, Antonio Augusto, Ph.D., M.D</au><au>Scherrer, Luciano, M.S</au><au>Koifman, Leandro, M.D</au><au>Magni, Fulvio, Ph.D</au><au>Ornellas, Maria Helena, M.D., Ph.D</au><au>Alves, Gilda, Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Experimental validation of the complement protein C3a down expression in the plasma of patients with squamous cell carcinoma of the penis</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>35</volume><issue>9</issue><spage>545.e13</spage><epage>545.e18</epage><pages>545.e13-545.e18</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>Abstract Objectives We have previously shown the importance of the complement system in differentiating between patients with squamous cell carcinoma of the penis (SCCP) and controls. These patients had low expression of C3a and C4 fragments. Therefore, in this study, we investigated the complement protein C3a as a potential circulating biomarker in these patients by a commercially available enzyme-linked immunosorbent assay (ELISA) test. Patients and methods Plasma samples from 39 patients with SCCP, 15 patients with prostate cancer, and 50 healthy male subjects were evaluated using the ELISA—Bioscience OptEIA Kit human anti-C3a (BD). The nonparametric Mann-Whitney test was used for comparison of means among the groups. Results The complement protein C3a was found down expressed in patients with SCCP ( P <0.05) in comparison to either subjects with good health or subjects with prostate cancer. Conclusion Experimental validation of the down expression of C3a was well succeeded using a commercial ELISA kit. Complement system fragment C3a is down expressed in patients with SCCP. Besides, C3a is also low expressed in the plasma of patients with initial prostate cancer when compared to healthy subjects. These results suggest that the innate immune response might be suppressed in patients with these malignancies.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28552465</pmid><doi>10.1016/j.urolonc.2017.05.002</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1439 |
| ispartof | Urologic oncology, 2017-09, Vol.35 (9), p.545.e13-545.e18 |
| issn | 1078-1439 1873-2496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1903438633 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Biomarkers, Tumor - metabolism Carcinoma, Squamous Cell - genetics Carcinoma, Squamous Cell - pathology Circulating biomarker Complement C3a - metabolism Enzyme-linked immunosorbent assay (ELISA) Enzyme-Linked Immunosorbent Assay - methods Healthy Volunteers Human complement C3a-desArg/C4a-desArg Humans Male Middle Aged Penile cancer Penile Neoplasms - genetics Penile Neoplasms - pathology Plasma Tumor microenvironment Urology |
| title | Experimental validation of the complement protein C3a down expression in the plasma of patients with squamous cell carcinoma of the penis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A29%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Experimental%20validation%20of%20the%20complement%20protein%20C3a%20down%20expression%20in%20the%20plasma%20of%20patients%20with%20squamous%20cell%20carcinoma%20of%20the%20penis&rft.jtitle=Urologic%20oncology&rft.au=Ornellas,%20Paulo,%20M.D&rft.date=2017-09-01&rft.volume=35&rft.issue=9&rft.spage=545.e13&rft.epage=545.e18&rft.pages=545.e13-545.e18&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2017.05.002&rft_dat=%3Cproquest_cross%3E1903438633%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1903438633&rft_id=info:pmid/28552465&rft_els_id=S1078143917302120&rfr_iscdi=true |